Global Distribution and Prevalence of Hepatitis C Virus Genotypes

Jane P. Messina,1 Isla Humphreys,2 Abraham Flaxman,3 Anthony Brown,2 Graham S. Cooke,4* Oliver G. Pybus,5* and Eleanor Barnes2*

Hepatitis C virus (HCV) exhibits high genetic diversity, characterized by regional variations in genotype prevalence. This poses a challenge to the improved development of vaccines and pan-genotypic treatments, which require the consideration of global trends in HCV genotype prevalence. Here we provide the first comprehensive survey of these trends. To approximate national HCV genotype prevalence, studies published between 1989 and 2013 reporting HCV genotypes are reviewed and combined with overall HCV prevalence estimates from the Global Burden of Disease (GBD) project. We also generate regional and global genotype prevalence estimates, inferring data for countries lacking genotype information. We include 1,217 studies in our analysis, representing 117 countries and 90% of the global population. We calculate that HCV genotype 1 is the most prevalent worldwide, comprising 83.4 million cases (46.2% of all HCV cases), approximately one-third of which are in East Asia. Genotype 3 is the next most prevalent globally (54.3 million, 30.1%); genotypes 2, 4, and 6 are responsible for a total 22.8% of all cases; genotype 5 comprises the remaining <1%. While genotypes 1 and 3 dominate in most countries irrespective of economic status, the largest proportions of genotypes 4 and 5 are in lower-income countries.

Conclusion: Although genotype 1 is most common worldwide, nongenotype 1 HCV cases—which are less well served by advances in vaccine and drug development—still comprise over half of all HCV cases. Relative genotype proportions are needed to inform healthcare models, which must be geographically tailored to specific countries or regions in order to improve access to new treatments. Genotype surveillance data are needed from many countries to improve estimates of unmet need. (HEPATOLOGY 2015;61:77-87)
middle income countries, despite treatment outcomes that are comparable to those in well-resourced settings. That said, the coming decade should witness a remarkable transformation in the treatment of HCV infection. While the first generation of new direct-acting antivirals (DAAs) were given in combination with interferon and ribavirin, and thus added to the burden of side effects, second-generation DAA therapies with minimal side effects and shortened courses of therapy are associated with cure rates of more than 90% in Phase II or III studies. Moreover, multiple DAA therapies targeting distinct HCV proteins have been developed and, when given in combination, will obviate the need for interferon treatment. Thus, if DAAs are made affordable, the treatment of HCV across the globe will become a realistic option for the first time.

HCV exhibits an extraordinarily high degree of genetic diversity—substantially greater than that of the HIV-1 pandemic—creating a major challenge for the development of both HCV vaccines and pan-genotypic drug therapies. At present, the duration of treatment, cure rates, and the need for adjuvant interferon and ribavirin with the new DAA therapies remain dependent in part on HCV genotype and subtype. Therefore, the development of national treatment strategies using DAA therapies requires a detailed understanding of relative HCV genotype prevalence and subtypes.

Furthermore, the first prophylactic T-cell vaccines that aim to prevent persistent HCV infection are currently in Phase II efficacy testing, with further candidates moving into human studies. The first generation of vaccines in development contain a subtype-1b immunogen in viral vectors that are deployed in a heterologous prime-boost regimen. In countries with mixed genotype infection, crossreactive immunity will depend on the generation of an immune response that targets HCV antigens that are conserved between genotypes. An alternative strategy, however, would be to develop geographically tailored vaccine immunogens for deployment at a country or regional level where detailed information on viral subtypes is available. Overall, the rational testing of HCV vaccine candidates will require a comprehensive country-level understanding of relative subtype prevalence.

HCV strains are classified into seven recognized genotypes (1-7) on the basis of phylogenetic and sequence analyses of whole viral genomes. HCV strains belonging to different genotypes differ at 30-35% of nucleotide sites. Within each genotype, HCV is further classified into 67 confirmed and 20 provisional subtypes. Strains that belong to the same subtype differ at <15% of nucleotide sites. The contemporary global geographic distribution of HCV genotypes is complex. It has already been established that a few subtypes—specifically 1a, 1b, 2a, and 3a—are widely distributed across the globe and account for a large proportion of HCV infections in high-income countries. These so-called “epidemic subtypes” are thought to have spread rapidly in the decades prior to the discovery of HCV by way of infected blood, blood products, injecting drug use, and other routes. Many other HCV subtypes are considered “endemic” strains; these are comparatively rare and have circulated for long periods of time in more restricted regions: endemic strains from genotypes 1 and 2 are primarily in West Africa, 3 in south Asia, 4 in Central Africa and the Middle East, 5 in Southern Africa, and 6 in South East Asia. To date, only one genotype 7 infection has been reported; it was isolated in Canada from a Central African immigrant. The global distribution of HCV genetic variation has likely been influenced by historical and contemporary trends in human migration. For example, strains from West Africa appear to have been transferred to the Americas by way of the transatlantic slave trade.

Here we are the first to estimate the relative prevalence of HCV genotypes globally by region and by country where data permitted. The data described provide a platform for the rational deployment and efficacy testing of new DAA therapies and vaccines for HCV.
Materials and Methods

We searched PubMed (www.pubmed.gov) for all articles containing the terms “HCV” or “hepatitis c virus” and “genotype” or “subtype” published between 1989 (the year that HCV was discovered) and 2013. As a standardized genotype classification system was not present before 1994, we converted HCV genotypes or serotypes in articles published between 1989 and 1994 to the consensus nomenclature proposed by Simmonds et al. In many studies HCV cases were classified at the genotype level but not at the subtype level. If articles contained the same patient cohort then this cohort was only counted once. We recorded the number of cases of each HCV genotype identified along with the size of the study population. Some individuals tested positive for more than one genotype; in such cases each genotype identified was given its own record. We did not include genotype 7 in the analysis (see introduction).

We summed the total numbers of HCV cases attributable to each genotype across all studies for each country. This enabled a straightforward calculation of the relative proportion of HCV infections comprised by each genotype. We then computed relative genotype frequencies for each Global Burden of Disease (GBD) region as defined by the World Health Organization (WHO). This allowed us to combine our genotype frequency estimates with recently published GBD estimates of overall HCV seroprevalence to estimate the numbers of genotype-specific cases within countries and regions as well as globally. Countries for which we were unable to obtain HCV genotype prevalence data were excluded from calculations of regional proportions, although their populations were included in the total population size of each region when generating regional genotype prevalence estimates. Since clinical studies of new DAA therapies have routinely been stratified by genotype 1 subtype, we examined the relative frequency of genotype 1 cases that were confirmed as either subtype 1a or 1b.

Mapping of genotype frequencies by country and region was performed using ArcGIS 9.3 (www.esri.com). The diversity of HCV genotypes present in each country was computed using the Shannon Diversity Index, resulting in a mappable score for each country that is a function of the number and relative frequency of genotypes identified within it. We also further stratified genotype prevalence by national income according to WHO income categories.

Results

In total, data from 1,217 studies were included in the analysis. A complete reference list for these is provided in the Supporting Information. The 117 countries for which information on HCV genotypes was found represent 90% of the world’s population and are listed in Table 1 by WHO GBD region, along with the number of studies for each country (the total number of virus samples by country is provided in Supporting Information Table S1). Unsurprisingly, Western Europe and North America had the greatest number of applicable studies. No studies meeting our search criteria were available for the Oceania GBD region (which does not include Australia), and the number of studies with HCV genotype information is relatively poor for the Caribbean, Central Latin America (outside of Mexico), and parts of Africa. Altogether, HCV genotype frequency information is available for ~60% of the world’s countries (79 out of 196), representing nearly 90% of the world’s population. The three most populous countries with no HCV genotype information are Bangladesh, Malaysia, and North Korea.

The relative prevalence of each HCV genotype by GBD region is mapped using pie charts in Fig. 1 and numerically in Table 2; the size of each chart is proportional to the number of regional seroprevalent HCV cases as estimated by Hanafiah et al. A complete breakdown of HCV genotype frequency information by country is provided in the Supporting Information (Table S1). Globally, genotype 1 is estimated to account for more HCV cases than any other genotype at 83.4 million (46.2%), with over one-third of genotype 1 cases located in East Asia. HCV genotype 3 is the next most common and is estimated to account for 54.3 million (30.1%) cases globally, approximately three-quarters of which occur in south Asia. Genotypes 2, 4, and 6 are responsible for the majority of the remaining cases of HCV worldwide, with an estimated 16.5 million (9.1%), 15.0 million (8.3%), and 9.8 million (5.4%) cases, respectively. East Asia accounts for the greatest numbers of genotype 2 and genotype 6 HCV cases, while North Africa and the Middle East have the largest number of genotype 4 cases. We estimate genotype 5 to be responsible for the fewest HCV cases globally (1.4 million, <1% of all HCV cases), the great majority of which occur in Southern and Eastern sub-Saharan Africa.

Figure 2A displays the most common genotype by country. Genotype 1 is the most common genotype in 85 of the 117 countries identified as having genotype
information in our study, and is highly prevalent worldwide. Of the 53% of genotype 1 cases for which the subtype was specified, we find 99% to be attributable to subtypes 1a and 1b (31% and 68%, respectively). A map showing the dominance of subtype 1a versus 1b in countries whose relative prevalence of genotype 1 exceeds 25% is provided in the Supporting Information (Fig. S5). We observed that genotype 2 dominated in West Africa, genotype 3 in south Asia and parts of Scandinavia, genotype 4 in Central and North Africa, Genotype 5 in South Africa, and genotype 6 in SE Asia.

The Shannon Diversity Index computed for each country is mapped in Fig. 2B. A low score indicates that most infections belong to one or two dominant genotypes, whereas a high score indicates that infections are more evenly distributed across several genotypes. The diversity of HCV genotypes varies considerably across countries, with few discernable geographic patterns. Diversity is high in China and many Southeast Asian countries, and also in Western Europe and Australia.

The absolute number of genotyped cases, and the numbers genotyped as a proportion of the population included in our survey, is shown for each country in Table S1 and Fig. 2C. Large sample sizes were available for the USA and many countries in Western

| Region/Country | Number of Studies | Region/Country | Number of Studies |
|----------------|-------------------|----------------|-------------------|
| Andean Latin America | 3 | North Africa and Middle East | 95 |
| Bolivia | 1 | Algeria | 2 |
| Peru | 2 | Egypt | 19 |
| Australasia | 20 | Iran (Islamic Republic of) | 9 |
| Australia | 19 | Iraq | 3 |
| New Zealand | 1 | Israel | 21 |
| Caribbean | 4 | Jordan | 1 |
| Cuba | 2 | Kuwait | 2 |
| Martinique | 1 | Lebanon | 3 |
| Suriname | 1 | Libyan Arab Jamahiriya | 1 |
| Central Asia | 18 | Morocco | 2 |
| Azerbaijan | 1 | Qatar | 2 |
| Georgia | 5 | Saudi Arabia | 4 |
| Mongolia | 8 | Syrian Arab Republic | 2 |
| Tajikistan | 1 | Tunisia | 6 |
| Turkmenistan | 1 | Turkey | 15 |
| Uzbekistan | 2 | United Arab Emirates | 3 |
| Central Europe | 43 | South Asia | 54 |
| Albania | 1 | Afghanistan | 1 |
| Bulgaria | 3 | India | 15 |
| Croatia | 6 | Nepal | 19 |
| Czech Republic | 1 | Pakistan | 19 |
| Hungary | 7 | Southeast Asia | 32 |
| Montenegro | 1 | Brunei Darussalam | 1 |
| Poland | 12 | Cambodia | 1 |
| Romania | 5 | Indonesia | 4 |
| Slovakia | 1 | Lao People’s Democratic Republic | 2 |
| Slovenia | 5 | Myanmar | 2 |
| The former Yugoslav Republic of Macedonia | 1 | Philippines | 1 |
| Central Latin America | 29 | Singapore | 2 |
| Colombia | 3 | Sri Lanka | 1 |
| Mexico | 22 | Thailand | 11 |
| Venezuela | 4 | Viet Nam | 7 |
| Central sub-Saharan Africa | 7 | Southern Latin America | 42 |
| Central African Republic | 2 | Argentina | 31 |
| Congo | 1 | Chile | 5 |
| Democratic Republic of the Congo | 1 | Uruguay | 6 |
| Equatorial Guinea | 1 | Southern sub-Saharan Africa | 6 |
| Gabon | 2 | Namibia | 1 |
| East Asia | 35 | South Africa | 5 |
| China | 35 | Tropical Latin America | 73 |
| Eastern Europe | 35 | Brazil | 73 |
| Belarus | 2 | Western Europe | 560 |
| Estonia | 2 | Austria | 38 |
| Latvia | 3 | Belgium | 19 |
| Lithuania | 3 | Cyprus | 2 |
| Republic of Moldova | 2 | Denmark | 10 |
| Russian Federation | 6 | Finland | 4 |
| Ukraine | 1 | France | 111 |
| Eastern sub-Saharan Africa | 9 | Germany | 62 |
| Eritrea | 1 | Greece | 32 |
| Ethiopia | 1 | Iceland | 1 |
| Kenya | 1 | Ireland | 9 |
Europe and Japan, whereas South America, Africa, parts of Eastern Europe, and Asia were relatively poorly sampled. Figure 3A,B displays six maps (one for each genotype) of the relative prevalence among all HCV genotypes by country. This figure reinforces the patterns seen in Fig. 2A for genotype 1, displaying its wide geographic extent and overall high prevalence worldwide. The frequency of genotype 3 cases is notably higher in south Asia but is comparatively lower in Africa (Fig. 3A). Genotypes 2, 4, 5, and 6 are typically more restricted in their extents. Genotype 4 frequencies are highest from central Africa to the Middle East, while genotype 5 only reaches higher frequencies in southern Africa (Fig. 3B). Lastly, genotype 6 is present at the highest frequencies in East and Southeast Asia, but is the dominant genotype in only one country—Laos (see Figs. 2A and 3B); it is also prevalent in neighboring Vietnam. These patterns are broadly consistent with previous informal summaries of the geographic structure of HCV genetic diversity.23,30,31

HCV cases in countries classified as high-income by the WHO were comprised of 66% of genotype 1, 18% genotype 3, 12% genotype 2, and small proportions of genotypes 4-6. Upper-middle income countries displayed a similar composition of HCV genotypes, although with a greater proportion of genotype 6 cases (11%). In contrast, the low and lower-middle income countries displayed relatively high proportions of genotypes 4 and 5. For the genotype proportions for all income classes, see the Supporting Information (Table S2).

### Discussion

The data presented here represent the most comprehensive effort to date to estimate the relative contribution of each HCV genotype to the global HCV epidemic. Such data are crucial to inform future prevention efforts (including vaccine design) as well as policies to ensure global access to the new generation.
Fig. 1. Relative prevalence of each HCV genotype by GBD region. Size of pie charts is proportional to the number of seroprevalent cases as estimated by Hanafiah et al.²

Fig. 2. (A) Countries by the majority genotype found across all associated studies. (B) Shannon Diversity Index for study countries, ranging from 0 (comprised of larger proportions of a few genotypes) to 1.2 (comprised of smaller proportions of many genotypes). (C) Number of genotyped virus samples across all studies by country.
of interferon-free DAAs. Aside from countries entirely lacking genotype information, our data highlight that the evidence base for genotype prevalence is weakest in Sudan, the Democratic Republic of the Congo, and Tanzania, in terms of the number of viruses genotyped as a proportion of their overall populations (Table S1; Fig. 2C). Of the world’s countries for which genotype data are missing, the largest populations are in Asia (accounting for 3.6% of the global population), followed by Africa (3.2% of the global population) and Latin America (1.4% of the global population). These regions typically represent areas of health neglect, and should be a priority for further surveillance as disease burden attributable to HCV is also likely to be high in these locations.

It is important to note that the most prevalent genotype in developed economies (genotype 1) is also the most prevalent globally and should be well served by interferon-free regimens of second-generation DAA therapies with viral eradication rates of >90%.13,32 Genotype 3, however, which accounts for ~30% of global infections, is not susceptible to the first generation of DAA protease inhibitors, and also appears less susceptible than other genotypes to sofosbuvir, the most advanced second-generation DAA therapy to date.33,34 Ultimately, should DAA therapies currently in development prove to be equally effective against all viral genotypes, viral genotyping will cease to be relevant to therapy. Even so, early data suggest that potential pan-genotypic combinations in late-stage development will continue to require stratification by viral genotype to define the optimal duration of drug therapy (e.g., sofosbuvir/GS5816 or MK5172/8472).35
One possible hypothesis for the current global distribution of genotype 1 is the chance association of subtypes 1a and 1b with the international dissemination of contaminated blood and blood products during the twentieth century, prior to the discovery of HCV in 1989. The global dissemination of genotype 3 is likely due to the association of subtype 3a with injection drug use and to population migration from countries where subtype 3a is dominant, such as India and Pakistan.

Although HCV genotype 1 and 3 infections are more prevalent than all other genotypes globally, genotypes found more commonly in lower-income countries still account for a significant proportion of HCV cases worldwide (Table S2). Specifically, genotype 2 is most frequent in West Africa and parts of South America (the latter likely reflecting population movements resulting from the trans-Atlantic slave trade), while genotypes 4 and 6 are common in Central/North Africa and East/Southeast Asia, respectively. We estimate that genotypes 2, 4, and 6 combined account for nearly one-quarter of all HCV cases globally. Although initial data suggest that genotype 2 will be relatively straightforward to treat in DAA interferon-free regimens, the need for more data about genotype 4 and 6 infections is a priority in order to inform local policies, especially in areas of highest prevalence.

Stratification by viral genotype at a national and regional level, and a better understanding of viral diversity within target populations, will also critically inform the rational design and testing of HCV vaccines. We have shown that diversity tends to be high...
in high-prevalence countries. The first T-cell vaccine, which hosts a genotype-1 immunogen, is currently undergoing efficacy testing in intravenous-drug user (IVDU) populations in Baltimore and San Francisco, where genotype 1 infection is dominant. Phase I clinical data suggest that the generation of T cells that target multiple viral genotypes using this vaccine is possible. Still, the roll-out of this and other HCV vaccines to other countries will require a detailed understanding of HCV genetic diversity within new target populations. Genotype diversity is particularly high in China and many Southeast Asian countries, and also in Western Europe and Australia, perhaps as a result of population immigration from Africa and/or Asia. In countries like these, vaccine efficacy at a population level would be dependent on the generation of crossreactive immunity; an alternative approach could also be the development of vaccines hosting different immunogens. In contrast, in countries where diversity is constrained such as Egypt (low diversity here is likely the result of the rapid amplification of subtype 4a during the twentieth century as a result of specific iatrogenic events), vaccine immunogens designed to most closely align with population HCV sequence may be the optimal strategy.

Our study is intended as a comprehensive literature survey and is not intended as a statistically formal meta-analysis. PubMed is the world’s largest medical library, and so we are confident in the comprehensiveness of our published literature base. However, we recognize that there are limitations within our dataset, and also that there may be some useful unpublished reports that were excluded from this study. Foremost among these is potential selection bias, since not all studies included were surveys of the general population (or proxies thereof, such as prospective blood donors). Thus, some risk groups associated with specific genotypes may be more readily sampled than others, and the impact of this may be strongest in those countries with the fewest number of genotyped cases. A mechanism for removing studies of certain risk groups would be required, and such a subjective decision could lead to additional sources of bias. In addition, we have not stratified studies according to the methodology used to genotype patients. Since the HCV RNA 5'UTR (untranslated region) is the most common target for diagnostic HCV RNA assays, it is also the viral region most commonly used to define viral genotype. While this region is relatively conserved, single nucleotide differences assessed using sequencing or probe-based assays are most commonly used in assays to define viral genotype. Importantly, these assays have been deemed adequate for current clinical applications. Although clinical assays that assess viral subtype also rely on 5'UTR as a substrate, the accuracy of HCV subtyping will be improved by additional sequencing of other viral regions such as core and NS5B. Overall, we believe errors arising from the misassignment of viral genotype to be limited. As a consequence of all the above, we have chosen not to provide confidence limits for our prevalence estimates, as we believe any such measure of uncertainty would be inappropriate without an explicit statistical sampling model. This is an important task for future refinements of the values reported here. Lastly, we have not addressed the contribution of each HCV genotype to the overall burden of morbidity and mortality due to acute infection, liver failure, or cirrhosis.

Our estimates of relative genotype prevalence are dependent on viral genetic data in association with global and national estimates of HCV prevalence based on seropositivity, which includes instances of cleared infections. Our estimates of relative genotype prevalence could be affected, therefore, if one genotype is cleared more readily than another. Comparison of spontaneous clearance rates between genotypes is unreliable since these have largely relied on the assessment of outbreak studies of single genotypes in distinct patient populations and are therefore subject to cohort bias. Consequently, the absolute number of cases attributable to each genotype reported here is most correctly interpreted as the number of infections of each genotype—past and present—that induced the seropositivity observed. Thus, if a country has undergone rapid, recent, and significant changes in relative genotype frequency, our absolute counts may be a poor proxy for the genotypes that characterize future incidence.

Although genotypes 1 and 3 account for the majority of infections worldwide, HCV strains belonging to the rarer genotypes 2, 4, 5, and 6 can increase rapidly in prevalence if they happen to become associated with efficient routes of transmission. The high prevalence and dominance of subtype 4a in Egypt is widely believed to have resulted from its spread by way of unsafe injections during past anti-schistosomal public health campaigns. Other subtypes have been amplified locally and regionally after being introduced into networks of injection drug users—for example, subtype 4d in Europe and subtype 6a in Vietnam and Hong Kong. These observations suggest that under the right circumstances, most, if not all, HCV genotypes have epidemic potential. They also suggest that social, behavioral, and demographic factors (including
international migration) are more important than viral genetic variation in determining the global prevalence of different genotypes.

References

1. Cooke GS, Lemoine M, Thurez M, Gore C, Swan T, Kamarulzaman A, et al. Viral hepatitis and the Global Burden of Disease: a need to regroup. J Viral Hepat 2013;20:600-601.

2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. HEPATOLOGY 2013;57:1333-1342.

3. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.

4. [52 Collaborators.] Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010;50:1387-1396.

5. Razavi H, Eklouhy AC, Elbasha E, Estes C, Paini K, Poynard T, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. HEPATOLOGY 2013;57:2164-2170.

6. Ford N, Kirby C, Singh K, Mills EJ, Cooke G, Kamarulzaman A, et al. Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bull WHO 2012;90:540-550.

7. Ford N, Singh K, Cooke GS, Mills EJ, von Schoen-Angerer T, Kamarulzaman A, et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis 2012;54:1465-1472.

8. Davies A, Singh KP, Shubber Z, Ducros P, Mills EJ, Cooke G, et al. Treatment outcomes of treatment-naive Hepatitis C patients co-infected with HIV: a systematic review and meta-analysis of observational cohorts. PloS One 2013;8:e55373.

9. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowey NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.

10. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.

11. Lawitz E, Laleza JP, Hassanain T, Kowdle KV, Poordad FF, Sheikh AM, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013;13:401-408.

12. Lawitz E, Poordad F, Kowdle KV, Cohen DE, Podasdecki T, Siggellows S, et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatology 2013;59:18-23.

13. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383:515-523.

14. Eyverson GT, Sims KD, Rodriguez-Torres M, Hezode C, Lawitz E, Boulienne M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014;146:420-429.

15. Timm J, Roggendorf M. Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol 2007;13:4808-4817.

16. Swadling L, Klenerman P, Barnes E. Ever closer to a prophylactic vaccine for HCV. Expert Opin Biol Ther 2013;13:1109-1124.

17. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012;4:135ra111.

18. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechtot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. HEPATOLOGY 1994;19:1321-1324.

19. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource. HEPATOLOGY 2014;59:318-327.

20. Smith DB, Pathirana S, Davidson F, Lawlor E, Power J, Yap PL, et al. The origin of hepatitis C virus genotypes. J Gen Virol 1997;78( Pt 2): 321-328.

21. Pybus OG, Cochrane A, Holmes EC, Simmonds P. The hepatitis C virus epidemic among injecting drug users. Infect Genet Evol 2005;5:131-139.

22. Magiorkinis G, Magiorkinis E, Paraskevi D, Ho SY, Shapiro B, Pybus OG, et al. The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med 2009;6:e1000198.

23. Simmonds P. The origin and evolution of hepatitis viruses in humans. J Gen Virol 2001;82:693-712.

24. Pybus OG, Barnes E, Taggart R, Lemey P, Markov PV, Rasachak B, et al. Genetic history of hepatitis C virus in East Asia. J Virol 2009;83:1071-1082.

25. Murphy DG, Willems B, Deschenes M, Hilzenrat N, Mousseau R, Sabbath S. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5’ untranslated region sequences. J Clin Microbiol 2007;45:1102-1112.

26. Markov PV, van de Loo TJ, Thomas XV, Aronson SJ, Wiegink CJ, van den Berk GE, et al. Colonial history and contemporary transmission shape the genetic diversity of hepatitis C virus genotype 2 in Amsterdam. J Virol 2012;86:7677-7687.

27. Murray CJ, Ezzati M, Flaxman AD, Lim S, Lopez R, Michaud C, et al. GBD 2010: design, definitions, and metrics. Lancet 2012;380:2063-2066.

28. Shannon CE. A mathematical theory of communication. Bell Syst Tech J 1948;27:379-423, 623-656.

29. Organization WH. World Health Statistics Annex 1: Regional and income groupings. Geneva, Switzerland: World Health Organization; 2013.

30. Pybus OG, Markov PV, Wu A, Tatem AJ. Investigating the endemic transmission of the hepatitis C virus. Int J Parasitol 2007;37:839-849.

31. Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int 2011;31(Suppl 2):1-3.

32. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanain T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic hepatitis C infection. N Engl J Med 2014;370:221-231.

33. Jacobson IM, Gordon SC, Kowdle KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-1877.

34. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanain T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.

35. McNally J. Safety and efficacy of sofosbuvir plus GS-5816 with or without ribavirin in treatment-naive subjects with chronic HCV infection. In: ClinicalTrials.gov, editor. NCT01858766: United States Food and Drug Administration; 2014.

36. Roman F, Hawotte K, Struck D, Ternes AM, Servais JY, Arendt V, et al. Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006. World J Gastroenterol 2008;14:1237-1243.
40. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000;355:887-891.
41. Germer JJ, Rys PN, Thorvilson JN, Persing DH. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol 1999;37:2625-2630.
42. Hara K, Rivera MM, Koh C, Sakiani S, Hoofnagle JH, Heller T. Important factors in reliable determination of hepatitis C virus genotype by use of the 5′ untranslated region. J Clin Microbiol 2013;51:1485-1489.
43. Laperche S, Lunel F, Izopet J, Alain S, Deny P, Duverlie G, et al. Comparison of hepatitis C virus NS5b and 5′ noncoding gene sequencing methods in a multicenter study. J Clin Microbiol 2005;43:733-739.
44. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-1233.
45. Esteban JL, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008;48:148-162.
46. de Bruijne J, Schinkel J, Prins M, Koekkoek SM, Aronson SJ, van Ballegooijen MW, et al. Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles. J Clin Microbiol 2009;47:3832-3838.
47. Fu Y, Qin W, Cao H, Xu R, Tan Y, Lu T, et al. HCV 6a prevalence in Guangdong province had the origin from Vietnam and recent dissemination to other regions of China: phylogeographic analyses. PloS One 2012;7:e28006.

Supporting Information

Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.27259/suppinfo.